Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorpora PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, finds itself at a critical juncture as it ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, finds itself at a critical juncture as it approaches ...

View the PRLD option chain and compare options of Prelude Therapeutics Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with ...